Free Trial

Aytu BioPharma Q4 2023 Earnings Report

Aytu BioPharma logo
$1.03 -0.04 (-3.74%)
As of 04/4/2025 04:00 PM Eastern

Aytu BioPharma EPS Results

Actual EPS
$0.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aytu BioPharma Revenue Results

Actual Revenue
$30.73 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aytu BioPharma Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Aytu BioPharma Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Aytu BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aytu BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aytu BioPharma and other key companies, straight to your email.

About Aytu BioPharma

Aytu BioPharma (NASDAQ:AYTU) is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

View Aytu BioPharma Profile

More Earnings Resources from MarketBeat